BPMX - BioPharmX Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue 1/31/2019 1/31/2018 1/31/2017 1/31/2016
Total Revenue 57 73 100 64
Cost of Revenue 83 250 427 237
Gross Profit -26 -177 -327 -173
Operating Expenses
Research Development 8,493 8,528 9,724 5,345
Selling General and Administrative 7,754.5 8,171 8,286 9,640
Non Recurring - - - -
Others - - - -
Total Operating Expenses 16,330.5 16,949 18,437 15,222
Operating Income or Loss -16,273.5 -16,876 -18,337 -15,158
Income from Continuing Operations
Total Other Income/Expenses Net -982.5 263 -67 -436
Earnings Before Interest and Taxes -16,273.5 -16,876 -18,337 -15,158
Interest Expense - - -141 -141
Income Before Tax -17,256 -16,638 -18,404 -15,594
Income Tax Expense 2 2 2 4
Minority Interest - - - -
Net Income From Continuing Ops -17,258 -16,640 -18,406 -15,598
Non-recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Changes - - - -
Other Items - - - -
Net Income
Net Income -17,258 -16,640 -18,406 -15,598
Preferred Stock And Other Adjustments - - - -
Net Income Applicable To Common Shares -17,258 -16,640 -18,532 -16,001